Naproxen Sodium | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Naproxen Sodium
HEALTH CANADA PATENTS

Evonik

Contact Supplier

Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Naproxen Sodium

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

29 API Suppliers, 22 USDMF, 7 CEP/COS, 4 EU WC, 34 KDMF, 11 NDC API, 9 Listed Suppliers, $ API Reference Price

29 API Suppliers
22 USDMF
7 CEP/COS
4 EU WC
34 KDMF
11 NDC API
9 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

FINISHED DOSAGE FORMULATIONS

148 FDF Dossiers, 85 FDA Orange Book, 11 Europe, 18 Canada, 4 South Africa, 30 Listed Dossiers

148 FDF Dossiers
85 FDA Orange Book
11 Europe
18 Canada
4 South Africa
30 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 500MG BASE, TABLET;ORAL - 220MG, TABLET, EXTENDED RELEASE;ORAL - EQ 375MG BASE, TABLET, EXTENDED RELEASE;ORAL - EQ 500MG BASE, TABLET, EXTENDED RELEASE;ORAL - EQ 750MG BASE, CAPSULE;ORAL - EQ 200MG BASE, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE

TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 500MG BASE
TABLET;ORAL - 220MG
TABLET, EXTENDED RELEASE;ORAL - EQ 375MG BASE
TABLET, EXTENDED RELEASE;ORAL - EQ 500MG BASE
TABLET, EXTENDED RELEASE;ORAL - EQ 750MG BASE
CAPSULE;ORAL - EQ 200MG BASE
TABLET;ORAL - 500MG;EQ 85MG BASE
TABLET;ORAL - 60MG;EQ 10MG BASE

RELATED EXCIPIENT COMPANIES

3 Evonik, 4 Rochem International Inc, 19 SPI Pharma, 2 Seqens, 9 DKSH, 2 Jai Radhe Sales, 11 Boai NKY Pharmaceuticals Ltd, 14 Gangwal Healthcare, 11 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 11 Actylis, 2 Aeon Procare, 1 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 33 BASF, 3 Clariant, 17 Corel Pharma Chem, 6 DFE Pharma, 2 Finar, 13 Gangwal Chemicals, 11 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 33 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 20 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 9 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 38 Roquette, 13 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 3 The Dow Chemical Company, 4 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

106 Fillers, Diluents & Binders, 65 Coating Systems & Additives, 49 Direct Compression, 44 Controlled & Modified Release, 43 Thickeners and Stabilizers, 43 Disintegrants & Superdisintegrants, 37 Solubilizers, 31 Granulation, 30 Parenteral, 30 Film Formers & Plasticizers, 25 Taste Masking, 24 Lubricants & Glidants, 24 Topical, 21 Co-Processed Excipients, 19 Chewable & Orodispersible Aids, 9 Empty Capsules, 9 API Stability Enhancers, 9 Emulsifying Agents, 9 Rheology Modifiers, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

106 Fillers, Diluents & Binders
65 Coating Systems & Additives
49 Direct Compression
44 Controlled & Modified Release
43 Thickeners and Stabilizers
43 Disintegrants & Superdisintegrants
37 Solubilizers
31 Granulation
30 Parenteral
30 Film Formers & Plasticizers
25 Taste Masking
24 Lubricants & Glidants
24 Topical
21 Co-Processed Excipients
19 Chewable & Orodispersible Aids
9 Empty Capsules
9 API Stability Enhancers
9 Emulsifying Agents
9 Rheology Modifiers
5 Surfactant & Foaming Agents
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 44 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
44 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 8 Finished Drug Prices

3 US Medicaid Prescriptions
8 Finished Drug Prices

MARKET PLACE

38 APIs, 2 FDF Dossiers

38 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

12 US Patents, 2 Health Canada Patents

12 US Patents
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 1 Others

3 EDQM
1 USP
1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 37 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 2Kirby Eades Gale Baker

filter Patent Reset all filters

2 All

01 22034096

filter Product Reset all filters

2 All

01 2Naproxen Sodium

filter Dosage Reset all filters

2 All

01 2Sustained Release Tablet

filter Exp Date Reset all filters

2 All

01 22011-01-14

Product Main Page

01

Kirby Eades Gale Baker

Naproxen Sodium

2024 ACI Convention

Not Confirmed

Kirby Eades Gale Baker

Country

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-01-14

Date Granted : 2002-03-26

Naproxen Sodium

Brand Name : NAPRELAN

Patent Number : 2034096

Filing Date : 1991-01-14

Strength per Unit : 375 mg

Dosage Form : Sustained Release Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-01-14

Date Granted : 2002-03-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Kirby Eades Gale Baker

Naproxen Sodium

2024 ACI Convention

Not Confirmed

Kirby Eades Gale Baker

Country

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-01-14

Date Granted : 2002-03-26

Naproxen Sodium

Brand Name : NAPRELAN

Patent Number : 2034096

Filing Date : 1991-01-14

Strength per Unit : 500 mg

Dosage Form : Sustained Release Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-01-14

Date Granted : 2002-03-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?